<p><strong>Pediatric Use</strong>: The safety and effectiveness of Eribulin&nbsp;in pediatric patients below the age of 18 years have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Study 1 did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Of the 827 subjects who received the recommended dose and schedule of Eribulin&nbsp;in clinical studies, 15% (121/827) were 65 and older, and 2% (17/827) patients were 75 and older. No overall differences in safety were observed between these subjects and younger subjects.<br />
<br />
<strong>Hepatic Impairment</strong>: A lower starting dose is recommended for patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh C) were not studied.<br />
<br />
<strong>Renal Impairment</strong>: A lower starting dose is recommended for patients with moderate (CrCl 30-50 mL/min) renal impairment. Patients with severe (CrCl &lt; 30 mL/min) renal impairment were not studied.</p>